Journal
MAYO CLINIC PROCEEDINGS
Volume 91, Issue 1, Pages 101-119Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2015.11.007
Keywords
-
Categories
Funding
- National Cancer Institute [CA 107476, CA186781, CA 168762]
- NATIONAL CANCER INSTITUTE [P50CA186781, R01CA168762, R01CA107476] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma. (C) 2016 Mayo Foundation for Medical Education and Research
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available